z-logo
open-access-imgOpen Access
Is cabozantinib the common answer to all radioiodine-refractory differentiated thyroid cancers?
Author(s) -
Akhil Kapoor,
Vijay M. Patil,
Kumar Prabhash
Publication year - 2022
Publication title -
cancer research statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_15_22
Subject(s) - cabozantinib , refractory (planetary science) , medicine , thyroid cancer , oncology , thyroid , cancer research , cancer , biology , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom